Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THROMBOLYSIS OF CANINE FEMORAL-ARTERY THROMBUS BY A NOVEL MODIFIED TISSUE-TYPE PLASMINOGEN-ACTIVATOR (E6010)
Autore:
SUZUKI N; SUZUKI S; NAGAOKA N; MIZUO H; YUZURIHA T; YOSHITAKE S; KANMATUSE K;
Indirizzi:
EISAI & CO LTD,TSUKUBA RES LABS,1-3 TOKODAI 5-CHOME TSUKUBA IBARAKI 30026 JAPAN SURUGADAI NIHON UNIV HOSP,DEPT INTERNAL MED 2,CHIYODA KU TOKYO 101 JAPAN
Titolo Testata:
Japanese Journal of Pharmacology
fascicolo: 3, volume: 65, anno: 1994,
pagine: 257 - 263
SICI:
0021-5198(1994)65:3<257:TOCFTB>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
MYOCARDIAL-INFARCTION; RABBITS; INVIVO; CLEARANCE; TURNOVER; DELETION; HEPARIN; FIBRIN; MODEL;
Keywords:
E6010 (NOVEL MODIFIED T-PA); PLASMINOGEN ACTIVATOR (TISSUE-TYPE); FEMORAL ARTERY THROMBUS MODEL; THROMBOLYTIC ACTIVITY; PLASMA CONCENTRATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
N. Suzuki et al., "THROMBOLYSIS OF CANINE FEMORAL-ARTERY THROMBUS BY A NOVEL MODIFIED TISSUE-TYPE PLASMINOGEN-ACTIVATOR (E6010)", Japanese Journal of Pharmacology, 65(3), 1994, pp. 257-263

Abstract

The thrombolytic activity of a novel modified tissue-type plasminogenactivator (t-PA) (E6010) was examined in a canine model with copper coil-induced femoral artery thrombus. This model, in which thrombolyticactivity can be easily and directly quantified by determining changesin thrombus weight, should be useful for comparing the activities of various thrombolytic agents. Using this model, the present study showed that the thrombolytic activity of bolus intravenous injection of E6010 was identical to that of continuous intravenous infusion of recombinant t-PA at the same dose. This thrombolytic activity can be explained by changes in blood concentrations of the administered thrombolytic agents. On the other hand, administration of the thrombolytic agents dose-dependently caused significant changes in the levels of hemostaticand fibrinolytic factors. These changes were not so marked with administration of E6010, and therefore we concluded that E6010 is unlikely to cause bleeding complications after administration.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 16:48:27